Agalsidase beta · Fabrazyme
Protein / enzyme therapeutic
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- FABRAZYME (agalsidase beta) is indicated for: • long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
- Fabry disease
- Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00837824 NCT00837824 · Fabry Disease, Chronic Kidney Disease, Stage IV (Severe) This study was randomized but not blinded, had no placebo control, and was terminated early after enrolling only a sixth of its planned patients; with just one clinical event recorded across both dose groups, it could not produce a meaningful comparison of Fabrazyme's effect on disease progression. Registry: NCT00837824 | 2 | Time to Clinically Significant Progression of Cardiac Disease, Cerebrovascular Disease, and/or Death Among Fabry Patients With Severe Kidney Disease (7 months) 2003-08 | Time to Clinically Significant Progression of Cardiac Disease, Cerebrovascular Disease, and/or Death Among Fabry Patients With Severe Kidney Disease (7 months): Fabrazyme 1mg/kg Every 2 Weeks 35 Days | Weak signal | link ↗ |
View 3 more trials
FIELD NCT00701415 · Fabry Disease This trial randomly assigned 31 treatment-naive boys with Fabry disease to one of two agalsidase beta dosing regimens. It was open-label, had no placebo group, and set the two active doses against each other rather than against an untreated comparison. Its primary endpoint was clearance of globotriaosylceramide from skin capillaries, a tissue marker rather than a measure of how patients feel or function, and the registry reports the figures without any statistical comparison between the doses. Registry: NCT00701415 | 3 | Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260) 2015-06 | Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). | Partial signal | link ↗ |
NCT00196716 NCT00196716 · Fabry Disease Every one of the 21 patients received the same open-label treatment with no randomization, no blinding, and no comparison group, so there is no way to know how much of the tissue clearance seen would have happened without treatment. The result describes a real before-and-after change, but the single-arm design keeps it as supportive rather than confirmatory evidence. Registry: NCT00196716 | 2 | Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium (Throughout study; 96 weeks) 2006-04 | Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase. | Weak signal | link ↗ |
NCT00074984 NCT00074984 · Fabry Disease Registry: NCT00074984 | 4 | Number of Participants Experiencing a Clinically Significant Renal, Cardiac or Cerebrovascular Event and/or Death in Fabrazyme (Agalsidase Beta) Patients as Compared to Placebo Patients (up to 35 months) 2004-01 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Alpha-galactosidase A (GLA / α-Gal A) drugs
Migalastat, pegunigalsidase alfa, isaralgagene civaparvovec. Compare all 4 Alpha-galactosidase A (GLA / α-Gal A) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Agalsidase Beta (Fabrazyme): this drug | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase. | |
| Migalastat (Galafold) | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | Partial signal | NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed | |
| Pegunigalsidase Alfa | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) | |
| Isaralgagene Civaparvovec | Phase 1/2 | Gene therapy / editing | Alpha-galactosidase A (GLA / α-Gal A) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.